Table III.

Linear regression analysis for correlation between clinicopathological factors and the GALNT14 ‘TT’ genotype.

	Univariate analysis			Multivariate analysis
Parameters	β	95% CI of β	P-value	β	95% CI of β	P-value
Sex, male	0.059	−0.117–0.117	0.510
Age, years	−0.003	−0.011–0.011	0.438
HBsAg-positive	−0.006	−0.214–0.214	0.952
Anti-HCV-positive	−0.053	−0.310–0.310	0.684
ECOG status	−0.103	−0.281–0.281	0.255
Cirrhosis	0.067	−0.166–0.166	0.568
Biliary tree stones	0.080	−0.133–0.133	0.461
Cholangitis (stone-unrelated)	0.068	−0.112–0.112	0.456
Tumor characteristics
Perihilar	0.113	−0.097–0.097	0.288
Invasion to vessels	0.120	−0.077–0.077	0.231
Perineural invasion	0.255	0.085–0.085	0.004a	0.185	0.014–0.014	0.035a
Periductal invasion	−0.002	−0.181–0.181	0.979
Lymph node involvement	0.060	0.027–0.027	0.001a	0.050	0.015–0.015	0.005a
Tumor number >1	0.158	−0.135–0.135	0.289
Tumor size (cm)	0.013	−0.014–0.014	0.339
Moderate/poor differentiation	−0.113	−0.322–0.322	0.288
Mixed hepatocellular carcinoma	−0.031	−0.295–0.295	0.819
Extrahepatobiliary invasion	0.134	−0.042–0.042	0.135
Resection margin involved	0.009	−0.170–0.170	0.918
>1 segment of resection	0.031	−0.234–0.234	0.819
Biochemistry
CEA, ng/ml	0.001	0.000–0.000	0.050
CA-19-9, ×1,000 U/ml	0.004	−0.001–0.001	0.103
Bilirubin, mg/dl	0.002	−0.026–0.026	0.870
AST, U/l	−0.00000257	−0.001–0.001	0.997
ALT, U/l	0.000	−0.001–0.001	0.667

CI, confidence interval; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; ECOG, Eastern Co-operative Oncology Group; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen 19-9; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GALNT14, N-acetylgalactosaminyltransferase 14.